Cargando…
Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the degradation of low-density lipoprotein (LDL) receptors; it has been proved that its inhibition improves cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD). Herein, we review the current...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Internal Medicine
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/ https://www.ncbi.nlm.nih.gov/pubmed/32921006 http://dx.doi.org/10.3904/kjim.2020.140 |